Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

NOVO-NORDISK A/S-SPONS ADR

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

Biotech

Large Cap

News

Eurozone

Health Care

General

Novo Nordisk busca la aprobación de la EMA para una dosis de 7,2 mg de Wegovy tras mostrar una pérdida de peso del 21 % en ensayos clínicos.

Novo Nordisk solicita aprobación en Europa para nueva dosis de Wegovy contra la obesidad

España investiga a Novo Nordisk por publicidad encubierta, mientras Reino Unido estudia factores genéticos en riesgos de medicamentos GLP-1.

Novo Nordisk bajo investigación:riesgos genéticos y posible publicidad encubierta en España

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Markets

AMGN

REGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs fundamentally altering consumer food purchasing patterns across America&#8217;s retail landscape.
What Happened: Big Chalk Analytics reports that users of glucagon-like peptide-1 receptor agonists, including Novo Nordisk A/S&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy alongside Eli Lilly and Co.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound, have significantly reduced their grocery expenditures. 
The firm&#8217;s survey of 4,500 consumers reveals an additional 8.3% of Americans plan to start these medications, potentially triggering $4.4 billion to $10.8 billion in further grocery losses.
Currently, 11.2% of U.S. adults use GLP-1 medications, with penetration potentially reaching 20% within twelve months. The drugs have generated grocery volume losses between 1.2% and 2.9%, while dollar sales dropped 0.9% to 2.3% across categories, according to Big Chalk&#8217;s analysis.
&#8220;GLP-1s have crossed the household-penetration threshold where their impact on grocery volumes and dollar sales can no longer be ignored,&#8221; said Rick Miller, partner at Big Chalk Analytics. &#8220;This is measurable, structural change.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/markets/tech/25/07/46460070/elon-musks-xai-faces-industry-backlash-over-reckless-ai-safety-practices-as-regulatory-scrutiny-intensifies" target="_blank" rel="noreferrer noopener">Elon Musk's xAI Faces Industry Backlash Over ‘Reckless' AI Safety Practices As Regulatory Scrutiny Intensifies</a>
Why It Matters: The appetite-suppressing effects have reshaped purchasing behavior across key categories. GLP-1 users demonstrate 65% higher likelihood of buying smaller cereal packages, 48% preference for reduced lunch meat portions, and 36% inclination toward smaller soft drink sizes.
&#8220;If grocery stores are seeing volume drops, we should expect lower prices under normal supply-demand dynamics,&#8221; Kevin Thompson, CEO of 9i Capital Group, <a href="https://www.newsweek.com/ozempic-costing-grocery-stores-billions-2099920">told</a> Newsweek. &#8220;That&#8217;s not materializing yet.&#8221;
The pharmaceutical sector faces additional headwinds as the Trump administration considers up to 200% tariffs on drug companies. Barclays <a href="https://www.benzinga.com/markets/equities/25/07/46435899/trumps-pharma-tariffs-can-hit-novo-nordisk-says-barclays-expert-but-its-difficult-to-predict-as-drugmakers-have-complex-supply-chains">warns such levies</a> would &#8220;inflate production costs, compress profit margins, and risk supply chain disruptions,&#8221; particularly impacting Novo Nordisk given its Danish manufacturing base for Wegovy&#8217;s active ingredients.
Long-term adherence data reveal sustainability challenges, with only 8.1% of patients maintaining GLP-1 obesity therapy after three years, though one-year Wegovy persistence <a href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert">improved from 33.2% in 2021 to 62.7% in 2024</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46458652/tim-cooks-new-job-is-keeping-trump-happy-says-economist-justin-wolfers-innovation-takes-a-back-seat-to-political-favoritism" target="_blank" rel="noreferrer noopener">Tim Cook&#8217;s New Job Is Keeping Trump ‘Happy,&#8217; Says Economist Justin Wolfers: ‘Innovation Takes A Back Seat To Political Favoritism&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by KK Stock via Shutterstock

Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles

<a href="https://x.com/Capitol_Forum/status/1945518260788637865" title="https://x.com/Capitol_Forum/status/1945518260788637865">https://x.com/Capitol_Forum/status/1945518260788637865</a>

The Capitol Forum Posts On X "Novo Nordisk: Company Did Not Report or Investigate Deaths Potentially Caused by Ozempic"

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said that it&#8217;s hard to predict which firm would be affected the most by these tariffs, except for Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Check out the current price of&nbsp;<a href="https://www.benzinga.com/quote/NVO">NVO stock here</a>.
What Happened: Explaining that the pharmaceutical companies as a whole are &#8220;out of favor&#8221; for tariffs, Field <a href="https://www.cnbc.com/video/2025/07/14/barclays-the-pharma-sector-is-very-out-of-favor-for-tariffs.html">told</a> CNBC that it was hard to single out a company that could be the most affected by the levies.
&#8220;It&#8217;s really difficult to say because they have really complex supply chains and companies like to keep it under the wraps,&#8221; she said, adding that &#8220;Novo Nordisk has been called out just because we know a lot of active pharmaceutical ingredients for Wegovy are manufactured in Denmark, so that&#8217;s just one that investors have highlighted.&#8221;
She adds, &#8220;But that could also just be because we have a more concrete idea of how their drug flows. But for the most part, this sector is just very out of favor for tariffs.&#8221;
Talking about the European pharma companies that were planning to invest in the U.S., Field mentioned Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Roche Holdings AG (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTCQX">RHHBY</a>), and AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
&#8220;We have seen from a number of European companies very significant announcements about manufacturing investments in the United States. We have seen that from Novartis, Roche, and we also know that the companies are working with the administration on this &#8216;Most Favored Nation&#8217; (MFN) drug pricing policy,&#8221; she said.
She also added that AstraZeneca is likely considering changing its registration to the U.S. &#8220;All of the companies based in Europe are emphasizing that they are very committed to the U.S. and manufacturing in the U.S.&#8221;
According to Field, this is all connected in some way. &#8220;It could be a combination of tariffs and drug pricing that the industry and administration can strike a deal that is favorable to both parties,&#8221; Field explained.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46400448/dan-ives-bets-on-cybersecurity-as-biggest-subsector-in-tech-for-2025-expects-strong-q2-earnings-from-crowdstrike-zscaler-palo-alto-check-point">Dan Ives Bets On Cybersecurity As &#8216;Biggest Subsector&#8217; In Tech For 2025; Expects Strong Q2 Earnings From CrowdStrike, Zscaler, Palo Alto, Check Point</a>
Why It Matters: Barclays has also <a href="https://www.benzinga.com/markets/equities/25/07/46364024/trump-threatens-200-pharma-tariffs-but-analyst-says-this-stock-is-immune-and-expected-to-benefit-from-levies">cautioned that a 200% pharma tariff</a> would &#8220;inflate production costs, compress profit margins, and risk supply chain disruptions." 
&#8220;We are waiting for the results of the Section 232 investigation from the Commerce Ministry, which is supposed to come by the end of the month. Prior to Trump saying that he was going to announce 200%, I think most have been expecting 25%; however, the industry&#8217;s response is that tariffs will be negative for patients, as it could result in drug shortages,&#8221; Feild said.
These are some pharma ETFs that could be impacted as the long-awaited industry-wide tariffs would be announced &#8220;very soon,&#8221; according to Trump.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>0.45%</td>
<td>-6.90%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>1.01%</td>
<td>-3.91%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-1.22%</td>
<td>-3.19%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-1.95%</td>
<td>-1.55%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>29.34%</td>
<td>33.78%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-3.88%</td>
<td>-8.36%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-18.59%</td>
<td>-24.16%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended mixed on Tuesday. The SPY was down 0.43% at $622.14, while the QQQ advanced 0.092% to $556.72, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
On Wednesday, the futures of the S&amp;P 500, Dow Jones, and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46386374/stanley-druckenmillers-duquesne-dumps-palantir-bets-big-on-this-dividend-play-which-has-surged-nearly-50-in-2025">Stanley Druckenmiller&#8217;s Duquesne Dumps Palantir, Bets Big On This Dividend Play Which Has Surged Nearly 50% In 2025</a></li>
</ul>
Photo courtesy: JHVEPhoto / Shutterstock.com

Equities

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$663.7K</td>
<td>1.8K</td>
<td>3.3K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$72.50</td>
<td>$44.4K</td>
<td>6.5K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$22.50</td>
<td>$89.6K</td>
<td>288</td>
<td>427</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$800.00</td>
<td>$45.5K</td>
<td>194</td>
<td>213</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$12.00</td>
<td>$56.2K</td>
<td>5.4K</td>
<td>130</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$70.00</td>
<td>$128.7K</td>
<td>1.3K</td>
<td>91</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/29/25</td>
<td>$59.00</td>
<td>$28.0K</td>
<td>2</td>
<td>56</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$40.00</td>
<td>$28.1K</td>
<td>1.6K</td>
<td>42</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$340.00</td>
<td>$59.2K</td>
<td>170</td>
<td>31</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$360.00</td>
<td>$25.0K</td>
<td>159</td>
<td>23</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 185 day(s) on January 16, 2026. This event was a transfer of 299 contract(s) at a $270.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $663.7K, with a price of $2220.0 per contract. There were 1803 open contracts at this strike prior to today, and today 3308 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a call option trade with bullish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 67 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $44.4K, with a price of $664.0 per contract. There were 6508 open contracts at this strike prior to today, and today 2208 contract(s) were bought and sold. 
• Regarding JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we observe a put option trade with bearish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 427 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $89.6K, with a price of $210.0 per contract. There were 288 open contracts at this strike prior to today, and today 427 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on July 25, 2025. Parties traded 50 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $45.5K, with a price of $910.0 per contract. There were 194 open contracts at this strike prior to today, and today 213 contract(s) were bought and sold. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with neutral sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 130 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $56.2K, with a price of $433.0 per contract. There were 5421 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 338 day(s) on June 18, 2026. Parties traded 132 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $128.7K, with a price of $975.0 per contract. There were 1300 open contracts at this strike prior to today, and today 91 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be neutral, expiring in 45 day(s) on August 29, 2025. This event was a transfer of 50 contract(s) at a $59.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $560.0 per contract. There were 2 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we notice a call option sweep that happens to be neutral, expiring in 31 day(s) on August 15, 2025. This event was a transfer of 35 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $805.0 per contract. There were 1699 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bullish sentiment. It expires in 549 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $59.2K, with a price of $2370.0 per contract. There were 170 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bullish sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 18 contract(s) at a $360.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $1390.0 per contract. There were 159 open contracts at this strike prior to today, and today 23 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BBIO

JANX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-1024x683.jpg" alt="" class="wp-image-15723" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-1024x683.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-300x200.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-768x512.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Follow-Up: Sana Biotechnology</h2>
6-Month Data, +150 % Rally, and Morgan Stanley's New Overweight Call
In a public <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">post </a>in May, I wrote about Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>), a biotech that has developed a potential cure for type 1 diabetes. Here's an update on developments since.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">1. Quick Recap of the May 19 Thesis</h3>
<ul class="wp-block-list">
<li>Functional-cure potential.&nbsp;Sana's hypo-immune (HIP) edits let donor islet cells make insulin without triggering rejection—no immunosuppression required.</li>
<li>Moat = immune stealth.&nbsp;Removing MHC I/II and adding "don't-eat-me" CD47 is the core advantage.</li>
<li>Industry disruption.&nbsp;If HIP-edited, stem-cell–derived islets (program SC451) scale, legacy diabetes franchises at&nbsp;Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>),&nbsp;Eli Lilly and Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>),&nbsp;DexCom, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>),&nbsp;Insulet Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), etc., may be at risk.</li>
</ul>
(See <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">original </a>post for full details.)
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">2. Stock Performance Since the Post</h3>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="740" height="151" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13.png" alt="" class="wp-image-15724" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13.png 740w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13-300x61.png 300w" sizes="(max-width: 740px) 100vw, 740px" /></figure>
In under eight weeks, SANA has&nbsp;nearly tripled, reflecting a shift from speculative promise to emerging proof-of-concept.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">3. Six-Month Human Data (June 23)</h3>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"Cells survived, secreted insulin, and responded to meals&nbsp;six months&nbsp;after transplant—without immunosuppression&nbsp;and with&nbsp;no safety issues."&nbsp;<a href="https://www.globenewswire.com/news-release/2025/06/23/3103540/0/en/Sana-Biotechnology-Announces-Positive-Six-Month-Clinical-Results-from-Type-1-Diabetes-Study-of-Islet-Cell-Transplantation-Without-Immunosuppression.html">GlobeNewswire</a>
</blockquote>
Why it matters
<ul class="wp-block-list">
<li>Durability:&nbsp;Continued C-peptide production and meal-stimulated spikes confirm functional beta-cell activity.</li>
<li>Immune evasion:&nbsp;Persistent graft survival validates HIP edits.</li>
<li>Safety:&nbsp;No cell- or procedure-related adverse events.</li>
<li>Path forward:&nbsp;Larger dose-escalation cohorts; IND for stem-cell version (SC451) targeted for 2026.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">4. Morgan Stanley Joins the Bull Camp (July 2)</h3>
<ul class="wp-block-list">
<li>Initiation:&nbsp;Overweight&nbsp;rating,&nbsp;$12 price target&nbsp;(~3× Friday's close).</li>
<li>Rationale: Six- and 12-week human data "de-risk the platform"; broad cell-engineering pipeline offers additional upside. Investing.com</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">5. What Could Move the Stock Next</h3>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Catalyst</th>
<th>Expected Timing</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional patients dosed</td>
<td>2H 2025 – 1H 2026</td>
<td>Reproducibility &amp; dose-response</td>
</tr>
<tr>
<td>Peer-review / ADA + IPITA presentations</td>
<td>2025 conf. season</td>
<td>External validation</td>
</tr>
<tr>
<td>SC451 IND filing</td>
<td>2026</td>
<td>Scalable, off-the-shelf therapy</td>
</tr>
<tr>
<td>Non-dilutive partnerships or grants</td>
<td>Anytime</td>
<td>Cash-burn mitigation</td>
</tr>
</tbody>
</table>
</figure>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">6. Bottom Line</h3>
<ul class="wp-block-list">
<li>Data + Duration:&nbsp;The six-month update converts "interesting science" into early evidence of&nbsp;durable clinical benefit.</li>
<li>Momentum:&nbsp;A ~150 % rally since May 19 shows the market is starting to price in that shift.</li>
<li>Institutional validation:&nbsp;Morgan Stanley's fresh&nbsp;Overweight&nbsp;adds credibility—and a higher-quality buyer base.</li>
</ul>
If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks to add. New capital? Size cautiously—it's still a single-patient read-out—but the upside/skew remains attractive as more data rolls in.
And if you're long legacy diabetes treatment companies, consider hedging them. Although Sana is aiming to cure T1 diabetes, its treatment could potentially impact the market for management of some forms of T2 diabetes as well (e.g., insulin therapy). As a reminder, you can use&nbsp;<a href="https://portfolioarmor.com/">Portfolio Armor's website</a>&nbsp;or&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">iPhone app</a>&nbsp;to scan for cost-effective hedges.
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-1024x683.jpeg" alt="" class="wp-image-15725" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
And if you want a heads up when we place our next trade, you can subscribe to the Portfolio Armor trading Substack below.&nbsp;
<figure class="wp-block-image size-full"><a href="https://blog.portfolioarmor.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1.jpg" alt="" class="wp-image-15726" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Opinion

Trading Ideas

DXCM

PODD

SANA

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes

WIIM

GILD

Shares of drug stocks are trading lower after the FDA reportedly indicated it could fast track drugs to companies that cut US prices in line with other countries.

JPMorgan Chase CEO Jamie Dimon issued a stark message to European leaders this week: the continent is steadily falling behind the United States, and financial markets now expose just how wide <a href="https://www.benzinga.com/markets/eurozone">the gap has become.</a>
At a conference in Dublin organized by Ireland's foreign ministry, Dimon warned that Europe is slipping in the global economic race. Over the past 10 to 15 years, he noted, the region's share of global output has dropped sharply compared to the U.S.
"Europe has gone from 90% U.S. GDP to 65% over 10 or 15 years. That's not good. You're losing," Dimon said.
He pointed to sluggish growth, outdated regulation, and insufficient investment as key reasons why the EU is falling behind both the U.S. and China.
While Dimon's focus was on economic differences in terms of GDP, the numbers coming out of stock markets reveal an even deeper structural divide between the U.S. and Europe.
<h2 class="wp-block-heading">Market Caps Tell An Even Bigger Divergence Story</h2>
The combined market capitalization of America's Magnificent Seven—Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)—has now soared past $18.3 trillion.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Top U.S. Tech Giants</th>
<th>Market Cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nvidia</td>
<td>$4.08T</td>
</tr>
<tr>
<td>Microsoft</td>
<td>$3.74T</td>
</tr>
<tr>
<td>Apple</td>
<td>$3.15T</td>
</tr>
<tr>
<td>Amazon</td>
<td>$2.39T</td>
</tr>
<tr>
<td>Alphabet</td>
<td>$2.20T</td>
</tr>
<tr>
<td>Meta</td>
<td>$1.81T</td>
</tr>
<tr>
<td>Tesla</td>
<td>$995B</td>
</tr>
<tr>
<td>Total</td>
<td>$18.37T</td>
</tr>
</tbody>
</table>
</figure>
By contrast, the top seven companies in Europe—including SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>), Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), Hermès International SCA (OTCPK: HESAY), LVMH Moët Hennessy Louis Vuitton SE (OTCPK: LVMUY), Roche Holding AG (OTCPK: RHHBY), and Nestlé S.A. (OTCPK: NSRGY)—are worth just $2.1 trillion combined.
The gap is staggering. The U.S. tech giants are now worth over nine times as much as Europe's largest companies.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Top EU Corporates</th>
<th>Market Cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP</td>
<td>$359B</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>$317B</td>
</tr>
<tr>
<td>ASML</td>
<td>$314B</td>
</tr>
<tr>
<td>Hermès</td>
<td>$303B</td>
</tr>
<tr>
<td>LVMH</td>
<td>$295B</td>
</tr>
<tr>
<td>Roche</td>
<td>$265B</td>
</tr>
<tr>
<td>Nestlé</td>
<td>$252B</td>
</tr>
<tr>
<td>Total</td>
<td>$2.11T</td>
</tr>
</tbody>
</table>
</figure>
Over the past 20 years, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – which tracks the S&amp;P 500 – has outperformed the SPDR DJ Euro STOXX 50 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEZ#NYSE">FEZ</a>) by a staggering 244%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11124301/image-139-1024x525.png" alt="" class="wp-image-982188" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11124301/image-139-1024x525.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11124301/image-139-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11124301/image-139-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11124301/image-139-1536x788.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11124301/image-139-2048x1051.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
"We've got this huge, strong market and our companies are big and successful, have huge kinds of scale that are global. You have that, but less and less," he said.
Dimon's comments add to growing concern across the continent. Last year, former European Central Bank chief Mario Draghi called for €800 billion per year in industrial investment to help Europe remain globally competitive.
Yet, despite repeated calls for reform, European stock markets continue to lag behind as U.S. firms dominate in scale, innovation and investor interest.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/eurozone/25/07/46354754/greece-stock-market-2025-rally-grek-etf-banks">The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025 </a></li>
</ul>
Photo: lev radin / Shutterstock.com

Tech

AAPL

AMZN

ASML

GOOGL

HESAY

LVMUY

MSFT

Nestle Sponsored representing Registered Shares Series B

NSRGY

NVDA

TSLA

Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing'

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is set to release its second-quarter earnings on August 7. According to&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a> data,&nbsp;analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.
Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growth prospects.
<h2 class="wp-block-heading">Analyst Adjustments and Forecasts</h2>
Ahead of the earnings release, Bank of America Securities (BofA) has made minor adjustments to its earnings model for Eli Lilly.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46319441/fda-approves-new-dosing-schedule-for-eli-lillys-kisunla-in-alzheimers-treatment" rel="noreferrer noopener">FDA Approves New Dosing Schedule For Eli Lilly&#8217;s Kisunla In Alzheimer&#8217;s Treatment</a>
BofA analyst Tim Anderson specifically noted a slight, low single-digit percentage increase in <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">second-quarter revenue</a> and EPS forecasts, primarily driven by stronger anticipated sales of Zepbound.
Looking further out, the analyst updated full-year projections, expecting total revenue to rise by 1% and 0.4% in 2025, with EPS growing by 1.9% in 2025 but experiencing a slight dip of 0.7% in 2026.
Beyond 2026, revenue and EPS projections largely remain consistent. Importantly, long-term forecasts for Lilly&#8217;s key products, Mounjaro, Zepbound, orforglipron, and retatrutide, have not seen significant revisions.
<h2 class="wp-block-heading">BofA Maintains Buy Rating</h2>
BofA maintains a Buy rating on Eli Lilly, with a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price forecast of $1,000</a>. This reflects the firm&#8217;s view of Lilly&#8217;s exceptional and sustainable growth potential compared to its peers, at what is considered a reasonable valuation.
The core focus of the company remains its incretin/GLP-1 drugs for obesity and diabetes, a market where Lilly is expected to maintain a leading position in the foreseeable future alongside one other top company.
<h2 class="wp-block-heading">Key Focus Areas for the Earnings Call</h2>
The earnings call will focus on several key areas. Broader concerns around U.S. drug pricing changes, including the &#8216;most favored nation&#8217; proposal and possible pharma-related tariffs under Section 232, are expected to be discussed.
Important upcoming clinical trial results, such as tirzepatide&#8217;s SURPASS-CVOT, orforglipron&#8217;s ATTAIN-1, and Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) REDEFINE-4, will also be a point of interest.
Performance updates on major products, especially Mounjaro and Zepbound, will be closely watched. Additionally, early launch progress for new drugs like Kisunla for Alzheimer&#8217;s and Ebglyss for eczema will be highlighted.
Price Action: LLY stock is trading higher by 0.82% to $784.07 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46324159/why-china-automotive-systems-stock-is-gaining-on-wednesday" target="_blank" rel="noreferrer noopener">Why China Automotive Systems Stock Is Gaining On Wednesday</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Earnings

Guidance

Price Target

Reiteration

Topics

Analyst Ratings

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">dose of its obesity treatment</a>, Wegovy (subcutaneous semaglutide 7.2 mg).
The submission is based on clinical data from the STEP UP and STEP UP T2D trials, investigating the efficacy and safety of semaglutide 7.2 mg in adults with obesity in STEP UP, and adults with obesity and type 2 diabetes in STEP UP T2D.
In the STEP UP trial, the <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916360" rel="noreferrer noopener">new</a> dose of Wegovy (semaglutide 7.2 mg) demonstrated a substantial average weight loss of 21% in people with obesity, with a third of participants losing 25% or more of their body weight compared with placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: ‘Coverage Is Not The Same As Access,' Says Expert</a>
Data also indicated that semaglutide 7.2 mg had a well-tolerated safety profile consistent with semaglutide 2.4 mg and the previous Novo Nordisk semaglutide trials.
Data from&nbsp;clinical trials&nbsp;also point to a slightly higher risk of developing the condition in people taking semaglutide compared with people taking a placebo (a dummy treatment).
In June, EMA's safety committee (PRAC) concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cause vision loss</a>.
After reviewing all available data on NAION with semaglutide, including data from non-clinical studies,&nbsp;clinical trials, post-marketing surveillance and the medical literature,&nbsp;the committee concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" rel="noreferrer noopener">people taking semaglutide)</a>.
<h2 class="wp-block-heading">Wegovy Vs. Mounjaro</h2>
Novo Nordisk launched Wegovy (semaglutide) in <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">India in June to compete</a> with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The first three will cost 4,336 rupees ($50.7), and the monthly cost will be 17,345 rupees ($201.4), similar to Eli Lilly's Mounjaro.
Some of Novo Nordisk's executives say the company allegedly ignored internal warnings that it was <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/07/46198535/novo-nordisk-ignored-internal-warnings-on-wegovy-launch-preparedness-report" rel="noreferrer noopener">unprepared to launch Wegovy</a>.
Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.
But the company has struggled to keep pace with Lilly's Zepbound, which has surpassed Wegovy in weekly new prescriptions this year.
Price Action: NVO stock is up 1.43% at $70.32 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46295652/wolfspeed-stock-continues-to-surge-whats-driving-the-momentum" target="_blank" rel="noreferrer noopener">Wolfspeed Stock Continues To Surge: What's Driving The Momentum?</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval

WW International, Inc. (WeightWatchers) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) announced on Tuesday&nbsp;the successful completion of its strategic reorganization process.
WeightWatchers implemented a financial reorganization transaction in May to strengthen its financial position and increase investment flexibility. The company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45239193/weightwatchers-takes-strategic-action-to-eliminate-1-15-billion-of-debt-strengthening-financial-po" rel="noreferrer noopener">eliminated $1.15 billion in debt</a>.
With this improved financial foundation, the company is well equipped to execute its transformation plan, which includes innovating its digital and member experience and accelerating the expansion of <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">its telehealth business</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/45073094/weightwatchers-integrates-with-eli-lilly-to-expand-access-to-zepbound-stock-skyrockets-110" rel="noreferrer noopener">WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%</a>
The company said in a press release in May that the business delivered 57% year-over-year revenue growth in the first quarter of 2025.
As part of this accelerated transformation, WeightWatchers made key leadership appointments. In its SEC <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/105319/000119312525156416/d83528dex991.htm" rel="noreferrer noopener">filing</a> on Tuesday, WeightWatchers said it appointed Dr.&nbsp;Kim Boyd as Chief Medical Officer to lead the company&#8217;s clinical vision, program development, and the integration of science into solutions for members.
&#8220;This is a pivotal moment for WeightWatchers,&#8221; said Tara Comonte, Chief Executive Officer of WeightWatchers. &#8220;With renewed financial strength, an expanded leadership team, and the addition of Dr.&nbsp;Boyd to lead clinical strategy and program innovation, we&#8217;re accelerating our transformation.&#8221;
Looking ahead, WeightWatchers will launch a new program later this year to support women through perimenopause, menopause, and postmenopause.
The offering builds upon WeightWatchers&#8217; existing program by delivering tailored nutritional and behavioral strategies with access to specialized clinical care, coaching, and community. The expansion into women&#8217;s health is a strategic move to address a broader gap in healthcare.
In addition to Dr. Boyd&#8217;s appointment, WeightWatchers has appointed Uta Knablein as Chief Product Officer to lead product strategy across the company&#8217;s expanding weight health platform.
As part of WeightWatchers&#8217; reorganization, a new Board of Directors will guide the company through its next growth phase.
Earlier in July, WeightWatchers announced an <a target="_blank" href="https://corporate.ww.com/news/news-details/2025/WeightWatchers-and-Novo-Nordisk-Expand-Collaboration-to-Improve-Medication-Access-Through-Trusted-Holistic-Model-of-Care/default.aspx" rel="noreferrer noopener">expanded</a> collaboration with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), which includes increased access to authentic, FDA-approved Wegovy (semaglutide) injection through WeightWatchers Clinic.
Additionally, Novo Nordisk is offering a limited-time savings offer available to WeightWatchers Clinic members. Starting July 1, 2025, eligible cash-pay members can access Wegovy at a reduced price of $299 until&nbsp;July 31, 2025.
In April, WeightWatchers announced a pharmacy integration with Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45066438/weightwatchers-streamlines-member-access-to-zepbound-vials-with-lillydirect-pharmacy-provider" rel="noreferrer noopener">pharmacy provider</a>, Gifthealth.
The integration will streamline access to Lilly&#8217;s FDA-approved Zepbound (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician.
The integration will streamline access to Zepbound by offering a vial format for eligible Zepbound self-pay patients without insurance coverage.
Gifthealth will fulfill on-label prescriptions for Zepbound vials written by board-certified clinicians. WeightWatchers members will receive real-time Rx tracking directly within the WeightWatchers App.
Price Action: WW stock is trading higher by 2.75% to $41.10 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46298240/voo-gets-some-love-as-investors-say-no-thanks-to-magnificent-7-stocks" target="_blank" rel="noreferrer noopener">VOO Gets Some Love As Investors Say &#8216;No Thanks&#8217; To Magnificent 7 Stocks</a></li>
</ul>
Photo by shisu_ka via Shutterstock

Movers

WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation

Novo Nordisk Submits Application To European Medicines Agency For Approval Of New Higher Dose Of Wegovy

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its head above parity. Nevertheless, the statistical winds may point to an eventual recovery which options traders could potentially exploit.
Fundamentally, in the post-pandemic era, sentiment toward Eli Lilly skyrocketed thanks to its <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">weight-loss drug</a>. In 2023, the U.S. Food and Drug Administration (FDA) approved the Zepbound (tirzepatide), the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. An injectable prescription medication that helps adults with other weight-related problems, Zepbound's clinical trials showed promising results.
Thanks to this early success, Eli Lilly and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) effectively formed a duopoly in the weight-loss market. While this reality contributed to a significant valuation surge, competition started to heat up last year. With major pharmaceuticals like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Roche Holding Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announcing advancements in the <a href="https://www.benzinga.com/general/biotech/24/07/39849867/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-wont-be-dominated-by-just-2">development of obesity-fighting drugs</a>, LLY stock entered into a frustrating consolidation channel.
Still, with the pharmaceutical giant incurring an extended period of red ink in the market, JPMorgan analyst Chris Schott is essentially making the case that Eli Lilly is undervalued. Specifically, prescriptions for Zepbound and Mounjaro (an injectable <a href="https://www.lilly.com/news/media/media-kits/mounjaro">medicine</a> for adults with type 2 diabetes) are running ahead of expectations in the second quarter. As such, this performance may allow the pharmaceutical to beat and raise guidance throughout 2025.
Even with the <a href="https://www.benzinga.com/content/45261458/is-eli-lilly-a-buy-after-weak-earnings-and-cvs-novo-partnership">formulary change</a> by CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) putting around 200,000 patients at risk of losing access, Schott states that Eli Lilly's market share — which stands at about 70% to 75% of new patients — and strong momentum may help the company easily absorb the impact.
<h2 class="wp-block-heading">Statistical Backdrop Could Point To A Recovery In LLY Stock</h2>
Although the fundamental narrative of LLY stock is intriguing, it may also be a presuppositional leap. Essentially, the conclusion that LLY is undervalued is already embedded in the premise (that the market is not fully pricing in the good news for Eli Lilly).
If one thinks about it, it's an extraordinary claim. LLY stock routinely ranks among the most actively traded securities. That the market is somehow mispricing the pharmaceutical giant is an assertion that requires extraordinary evidence. In my opinion, if such evidence exists, it will likely materialize in the statistical realm as it's the arena that few (if any) analysts venture into.
A significant barrier to statistical analysis of the financial markets is the deployment of continuous scalar signals, such as share price or various valuation ratios. Because these signals are non-stationary, it's difficult (if not outright impossible) to extract meaningful insights based on the frequency of past analogs. Especially for highly traded securities like LLY stock, the measurement metrics constantly fluctuate.
To remedy this problem, we can impose stationarity by converting scalar signals into discrete states. For analyzing securities, converting share price into market breadth or sequences of accumulative and distributive sessions carries significant advantages. First, market breadth is essentially a representation of demand and demand is effectively binary. Second, clusters of binary codes can form distinct behavioral states, which can then serve as past analogs for extracting forward probabilities.
As an example, in the trailing two months, the price action of LLY stock can be interpreted as a "6-4-D" sequence: six up weeks, four down weeks, with a negative trajectory across the 10-week period. Admittedly, this process pancakes LLY's magnitude dynamism into a simple binary code. But the benefit is that this code can be easily segregated into distinct market profiles. From there, we can observe the likelihood of transition from one state to another.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-975331" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
With the above framework, we can identify that since January 2019, the 6-4-D sequence has materialized 38 times. From past analogs, we can also determine that in 68.42% of cases, the following week's price action results in upside, with a median return of 2.47%.
Accounting for the volatility on Monday, a realistic target over the next three weeks — assuming that the bulls gain and maintain control of the market — is just under the $800 level.
<h2 class="wp-block-heading">Playing The Odds With Eli Lilly</h2>
Based on the market intelligence above, bold speculators may consider the 785/790 bull call spread expiring Aug. 1. This transaction involves buying the $785 call and simultaneously selling the $790 call, for a net debit paid of $255 (the most that can be lost in the trade). Should LLY stock rise through the short strike price ($790) at expiration, the maximum reward is $245, a payout of 96%.
To be sure, the 780/790 bull spread expiring on the same day offers a payout of nearly 113%. However, the net debit required is $470, which puts significantly more capital at risk for only a modest increase in payout. Therefore, the 785/790 call spread is arguably more tempting.
Either way, both transactions require LLY stock to hit or exceed $790 on Aug. 1, which empirically appears to be a reasonable target. As a baseline, the chance that a long position in LLY will be profitable on any given week is quite high at 60.29%. However, the market's response to the 6-4-D sequence amplifies the odds in favor of the bullish speculator, thus incentivizing a debit-based strategy.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46253955/khc-stock-bearish-pressure-statistical-reversal">Options Corner: Why Kraft Heinz Could Flip The Script On The Bears</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is currently experiencing a decline in its stock price, trading lower on Monday. The company&#8217;s stock has plummeted approximately 18% over the past month, reflecting recent challenges.
A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) ended its collaboration with Hims &amp; Hers. Consequently, Hims &amp; Hers will no longer have direct access to Wegovy, Novo Nordisk&#8217;s popular GLP-1 weight-loss drug, through the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46050799/hims-hers-health-stock-is-tumbling-monday-whats-happening" rel="noreferrer noopener">NovoCare Pharmacy</a>.
Novo Nordisk stated in a press release that the termination was due to Hims &amp; Hers Health&#8217;s alleged failure to adhere to laws prohibiting mass sales of compounded drugs under the false guise of &#8220;personalization&#8221; and its use of deceptive marketing practices, which Novo Nordisk claimed disregarded patient safety.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can&#8217;t Afford Long-Term Use: &#8216;Coverage Is Not The Same As Access,&#8217; Says Expert</a>
This split represents the latest challenge facing Hims &amp; Hers, even as the company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030.
Hims &amp; Hers Health shares are under pressure largely because the firm sells cheaper, compounded versions of popular weight-loss drugs. Regulators typically permit compounded versions of drugs to enter the market to meet demand when there&#8217;s an official shortage of the brand-name product.
However, the FDA announced earlier this year that semaglutide, the active ingredient in Wegovy, had been removed from the drug shortage list, indicating that supply was now sufficient to meet current and projected demand. This change had a notable impact on Hims &amp; Hers.
Despite this, the company reported significant success in its GLP-1 offerings, generating over <a target="_blank" href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening" rel="noreferrer noopener">$225 million in revenue</a> in 2024 from these products. The ongoing legal and regulatory scrutiny now centers on the legality of mass-producing compounded versions once the official shortage is declared over.
Morgan Stanley, in a Monday note, highlighted an &#8220;increased focus on both the legal and business implications that could influence the stock.&#8221; Analysts spoke with two experts to gain insight into these implications, particularly concerning Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">lawsuits against compounders</a>.
Analyst Craig Hettenbach says that Expert #1 cautiously advised compounding pharmacies to cease large-scale production of GLP-1 drugs once the shortage ends, acknowledging that business owners have varying levels of risk tolerance.
Expert #2 offered a more nuanced perspective, suggesting there might be a legitimate case for compounding GLP-1s under 503A for specific patient groups, even if the drugs are not individually tailored. Nevertheless, Expert #2 admitted that little legal precedent supports this view and believed that merely adding a vitamin to a GLP-1 would likely not render the product legally compliant under 503A, a common practice among some compounders.
Both experts indicated that even if the current cases are dismissed, Eli Lilly could refile with stronger arguments. Presently, the compounders are seeking dismissal of the lawsuits, contending that Eli Lilly, as a private company, cannot make certain claims that fall solely under the FDA&#8217;s jurisdiction.
The two experts discussed whether it would be helpful to ask for a preliminary injunction, a court order to stop the compounders from operating during the case. Expert #2 thinks it will be hard for Lilly to get one because the company would need to prove it&#8217;s suffering serious, irreversible harm.
Without that injunction, the compounders can keep running their businesses while the cases are ongoing. Both experts stressed that each case depends heavily on the specific facts, so gathering evidence and going through the legal process will take time. A final decision in these cases will probably take 2 to 3 years.
In light of these developments, Morgan Stanley has maintained its Equal Weight rating on Hims &amp; Hers Health, with <a target="_blank" href="https://www.benzinga.com/quote/HIMS/analyst-ratings" rel="noreferrer noopener">a price forecast of $40</a>.
Earlier in June, the company announced a significant step in its global expansion through its agreement to acquire ZAVA, a <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45779301/hims-hers-zava-acquisition-deal-expands-its-market-opportunity-by-52-billion-analyst" rel="noreferrer noopener">digital health platform in Europe</a>.
The strategic move will expand Hims &amp; Hers&#8217; footprint in the United Kingdom and officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.
Price Action: HIMS stock is trading lower by 5.51% to $45.38 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance" target="_blank" rel="noreferrer noopener">Molina Healthcare Says Higher Medical Cost Trends Bite, Cuts Profit Guidance</a></li>
</ul>
Image by T. Schneider via Shutterstock

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.
What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent across plans. &#8220;Coverage is not the same as access,&#8221; said Beverly Tchang, a New York-based physician who advises both Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), reported <a href="https://apnews.com/article/wegovy-zepbound-obesity-drugs-coverage-access-142e234c16df4443e8f66c27d01f44e2#">the</a> Associated Press.
GLP-1 receptor agonists continue driving substantial revenue for both drugmakers. Zepbound generated $2.3 billion in U.S. first-quarter sales, while Wegovy contributed nearly $1.9 billion with approximately 200,000 weekly prescriptions domestically.
Insurance coverage varies dramatically by provider and plan type. Novo Nordisk reports that 85% of covered U.S. patients pay $25 or less monthly. However, most state Medicaid programs and Medicare exclude obesity coverage, forcing patients to shoulder hundreds in out-of-pocket costs monthly, according to the report.
See Also: <a href="https://www.benzinga.com/markets/large-cap/25/07/46269182/ai-assistants-could-break-amazons-60-billion-retail-media-business-warns-vc-its-not-just-search-at-google-its-search-everywhere">AI Assistants Could Break Amazon&#8217;s $60 Billion Retail Media Business, Warns VC: &#8216;It&#8217;s Not Just Search At Google — It&#8217;s Search Everywhere&#8217;</a>
Why It Matters: The regulatory landscape remains complex regarding compounded versions. Despite FDA determinations that drug shortages ended, compounding pharmacies continue selling cheaper alternatives under personalization exceptions.
Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) offers compounded semaglutide starting at $165 monthly, leading to legal challenges from Eli Lilly.
Recent pricing trends show that both companies reduced uninsured patient costs by several hundred dollars from initial launch prices. However, $500 monthly represents approximately 14% of the average U.S. per-capita income at $43,000 annually.
Long-term adherence data reveals persistence challenges that could impact market expansion. Real-world studies show only 8.1% of patients maintained GLP-1 obesity therapy after three years, though one-year persistence for Wegovy <a href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows">improved from 33.2% in 2021 to 62.7% in 2024</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46268630/alphabet-backed-drug-discovery-firm-nears-human-trials-of-ai-developed-remedies-says-president-the-next-big-milestone-is">Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: &#8216;The Next Big Milestone Is…&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tobias Arhelger / Shutterstock.com

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$157.50</td>
<td>$94.8K</td>
<td>1.5K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/11/25</td>
<td>$30.00</td>
<td>$25.7K</td>
<td>980</td>
<td>1.0K</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$29.5K</td>
<td>10</td>
<td>899</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$307.50</td>
<td>$37.3K</td>
<td>1.1K</td>
<td>437</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$20.00</td>
<td>$37.7K</td>
<td>1.0K</td>
<td>431</td>
</tr>
<tr>
<td>PRME</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$27.5K</td>
<td>24</td>
<td>100</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$60.00</td>
<td>$161.0K</td>
<td>827</td>
<td>100</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.00</td>
<td>$46.7K</td>
<td>14.6K</td>
<td>67</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$75.00</td>
<td>$26.5K</td>
<td>387</td>
<td>61</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$340.00</td>
<td>$90.7K</td>
<td>11</td>
<td>56</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on July 18, 2025. Parties traded 465 contract(s) at a $157.50 strike. The total cost received by the writing party (or parties) was $94.8K, with a price of $204.0 per contract. There were 1504 open contracts at this strike prior to today, and today 1579 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on July 11, 2025. This event was a transfer of 211 contract(s) at a $30.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $122.0 per contract. There were 980 open contracts at this strike prior to today, and today 1094 contract(s) were bought and sold. 
• Regarding CNC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), we observe a call option sweep with bullish sentiment. It expires in 198 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $35.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $590.0 per contract. There were 10 open contracts at this strike prior to today, and today 899 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bearish, expiring in 16 day(s) on July 18, 2025. This event was a transfer of 65 contract(s) at a $307.50 strike. The total cost received by the writing party (or parties) was $37.3K, with a price of $575.0 per contract. There were 1172 open contracts at this strike prior to today, and today 437 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option trade that happens to be bearish, expiring in 142 day(s) on November 21, 2025. This event was a transfer of 65 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $37.7K, with a price of $580.0 per contract. There were 1022 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• For PRME (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on October 17, 2025. This event was a transfer of 100 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $275.0 per contract. There were 24 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option trade that happens to be bullish, expiring in 898 day(s) on December 17, 2027. This event was a transfer of 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $161.0K, with a price of $1610.0 per contract. There were 827 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 198 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $46.7K, with a price of $4673.0 per contract. There were 14663 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bullish sentiment. It expires in 142 day(s) on November 21, 2025. Parties traded 45 contract(s) at a $75.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $590.0 per contract. There were 387 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• Regarding ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we observe a call option sweep with bearish sentiment. It expires in 79 day(s) on September 19, 2025. Parties traded 24 contract(s) at a $340.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $90.7K, with a price of $3768.0 per contract. There were 11 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

MRNA

PRME

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) executives allegedly ignored internal warnings that the company was unprepared to launch its <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obesity drug Wegovy</a>.
As rival Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early decisions.
Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46139132/spain-accuses-novo-nordisk-of-covert-advertising-for-prescription-weight-loss-drugs" rel="noreferrer noopener">Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs</a>
But the company has struggled to keep pace with Lilly&#8217;s Zepbound, which has surpassed Wegovy in weekly new prescriptions this year.
Amid concerns over its competitiveness in the weight-loss market, Novo is undergoing a leadership shake-up, including <a target="_blank" href="https://www.benzinga.com/news/management/25/05/45466201/ozempic-maker-novo-nordisk-looks-for-new-chief-jorgensen-steps-down" rel="noreferrer noopener">the recent dismissal</a> of CEO Lars Fruergaard Jorgensen and earlier departures like U.S. chief Doug Langa.
Sources told Reuters that during tense internal meetings, sales and marketing staff warned Langa about launching Wegovy too quickly after FDA approval.
They urged a delay until supply and insurance coverage were more secure. With a <a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">list price of up to $1,300 per month</a>, many patients found the drug unaffordable without insurance, and Novo missed an opportunity to build a more stable launch pad while Lilly&#8217;s market entry was still years away.
However, company leadership in Copenhagen held to conservative sales expectations through 2025, Reuters report highlighted, underestimating the scale of demand driven by the global obesity epidemic. Former employees said Novo had internal indicators pointing to stronger uptake but failed to adjust its strategy accordingly.
The consequences were swift. Wegovy&#8217;s launch was plagued by supply shortages, leaving patients without doses and discouraging new users. The high cost also pushed some patients toward the gray market of compounded drugs.
Novo further faced criticism for pricing Wegovy significantly higher than its diabetes drug Ozempic, while Lilly entered the market with Zepbound at $1,080 and provided steep discounts through its LillyDirect pharmacy.
One former insider claimed that Novo hesitated to offer competitive rebates to pharmacy benefit managers (PBMs), limiting the drug&#8217;s accessibility.
This reluctance hurt relationships with insurers and failed to secure broader coverage, placing Novo at a disadvantage compared to Lilly&#8217;s aggressive pricing and reimbursement strategies.
Recently, Novo Nordisk launched its weight-loss drug Wegovy (semaglutide) in India to <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">compete with Eli Lilly</a>.
Price Action: NVO stock is trading higher by 0.13% to 69.11 at last check Tuesday.
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/07/46192989/mesoblast-targets-accelerated-fda-approval-for-heart-failure-drug-revascor" target="_blank" rel="noreferrer noopener">Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Media

Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?
<ol class="wp-block-list">
<li>Circle Internet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) stock fell 24.91% amid a pullback after recent highs. The drop <a href="https://www.benzinga.com//node/46056731" target="_blank" rel="noreferrer noopener">followed its announcement</a> of its partnership with Fiserv to integrate its stablecoin platform into Fiserv's banking and payment solutions.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock declined 23.06% amid reports that Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a href="https://www.benzinga.com//node/46067629" target="_blank" rel="noreferrer noopener">terminated its collaboration</a> with the company.</li>
<li>Vonage Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VG#NASDAQ">VG</a>) stock plunged 17.46% after BofA Securities maintained a Buy rating on Venture Global stock and <a href="https://www.benzinga.com/quote/VG/analyst-ratings" target="_blank" rel="noreferrer noopener">raised its price forecast</a> to $18.5.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) stock fell 12.86% after the <a href="https://www.benzinga.com//node/46087245" target="_blank" rel="noreferrer noopener">company priced its offering</a> of nearly 90 million shares at $22.25 per share.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) stock dipped 12.85% amid profit-taking <a href="https://www.benzinga.com//node/46146598" target="_blank" rel="noreferrer noopener">after a recent surge</a>. HC Wainwright &amp; Co. initiated coverage <a href="https://www.benzinga.com//node/46102704" target="_blank" rel="noreferrer noopener">with a Neutral rating</a>.</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) stock dropped 12.79% after DA Davidson maintained a Buy rating but lowered its <a href="https://www.benzinga.com/quote/DUOL/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast to $500</a>.</li>
<li>Equinix, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) stock declined 11.07% after several analysts <a href="https://www.benzinga.com/quote/EQIX/analyst-ratings" target="_blank" rel="noreferrer noopener">cut their price forecasts</a>.</li>
<li>Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) stock plunged 9.58% amid easing geopolitical tensions between Iran and Israel. President Trump's statement allowing China to buy Iranian oil and the company's North Sea project approval also added pressure.</li>
<li>CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) stock fell 9.34% despite Morgan Stanley and Wells Fargo raising their price forecasts while maintaining <a href="https://www.benzinga.com/quote/CF/analyst-ratings" target="_blank" rel="noreferrer noopener">neutral or overweight ratings</a>.</li>
<li>Ecopetrol S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) stock decreased 9.25% after it extended its agreement to cut ADR conversion fees by 50%. The broader energy sector also declined following a mild Iranian attack that caused oil prices to slip.</li>
</ol>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46159607/nike-aerovironment-and-coinbase-are-among-top-10-large-cap-gainers-last-week-june-23-27-are-the-others-in-your-portfolio">Nike, AeroVironment And Coinbase Are Among Top 10 Large Cap Gainers Last Week (June 23-27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by PJ McDonnell from Shutterstock

CRCL

CRWV

DUOL

EQIX

EQNR

Circle Internet, Hims & Hers Health And CoreWeave Are Among Top 10 Large Cap Losers Last Week (June 23-27): Are The Others In Your Portfolio?

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
Wall Street surged this week as easing geopolitics and a potential pause in U.S.-China tariffs lifted sentiment. The S&amp;P 500 and Nasdaq hit record highs, boosted significantly by Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), whose stock jumped by about 10% to record its highest valuation — $3.8 trillion — overtaking Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) as the world's most valuable company
The tech rally reflected strong earnings from Nvidia's AI-centric chip business and supplier Micron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), while broader market gains were bolstered by renewed risk appetite in equities.
Next week, investors will track the June jobs report, rhetoric on tariffs — including the July 8 "Liberation Day" deadline — and upcoming July 4 tax‑and‑spending legislative actions that could influence rates and yields.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/markets/tech/25/06/46081553/nvidias-jensen-huang-sparks-quantum-stock-frenzy">"Nvidia's Big Moment Is Back—Stock Soared 500% The Last Time This Happened"</a>, by Piero Cingari, reports that Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is forming a bullish golden cross — a 50-day moving average crossing above the 200‑day — after recovering from earlier tariff-induced weakness, which historically has preceded massive rallies, with gains as high as 800%, fueled by easing U.S.-China trade tensions and strong earnings.
<a href="https://www.benzinga.com/markets/earnings/25/06/46104401/micron-q3-earnings-revenue-eps-beat-estimates-data-center-revenue-guidance-ai-demand">"Micron Q3 earnings: Revenue, EPS beat estimates as data center revenue doubles, strong guidance on rising AI‑driven demand"</a>, by Adam Eckert, reports that Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) delivered a strong Q3 with $9.3 billion in revenue (beating $8.87 billion estimates) and $1.91 adjusted EPS (versus $1.60 expected); data-center revenue more than doubled, and the company forecast Q4 revenue of $10.7 billion and EPS of $2.50 amid surging AI memory demand.
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46098312/palantir-stock-hits-all-time-high-whats-going-on">"Palantir stock hits all‑time high: what's going on?"</a>, by Adam Eckert, reports that Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares reached record highs — up roughly 500% over the past year and 93% year-to-date — driven by strong momentum (Benzinga Pro momentum score of 99), surging AI and government contracts including a $795 million U.S. Army deal, and positive Wall Street sentiment such as Loop Capital's raised price target.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/markets/earnings/25/06/46084802/blackberry-stock-climbs-after-better-than-expected-q1-report-details">BlackBerry Stock Climbs After Better-Than-Expected Q1 Report: Details</a>
<a href="https://www.benzinga.com/markets/commodities/25/06/46120819/platinum-miners-forecasts-stocks">Platinum's Biggest Rally In 40 Years: These 6 Mining Stocks Could Be Top Gainers</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46129177/pony-ai-stock-pops-on-report-uber-is-in-talks-with-travis-kalanick-to-invest-in-potential-deal">Pony AI Stock Pops On Report Uber Is In Talks With Travis Kalanick To Invest In Potential Deal</a>

The Bears
<a href="https://www.benzinga.com/trading-ideas/technicals/25/06/46080036/hims-crashes-on-novo-glp-1-fallout-buy-the-dip-or-bail">"HIMS crashes on Novo GLP‑1 fallout: buy‑the‑dip or bail?"</a>, by Surbhi Jain, reports that Hims &amp; Hers Health Inc. (NYSE: HIMS) shares plunged 34% after Novo Nordisk (NYSE: NVO) ended their partnership over claims of unapproved Wegovy compounding, with analysts warning that legal risk and lofty valuation may outweigh oversold technicals.
<a href="https://www.benzinga.com/news/health-care/25/06/46116103/altimmune-stock-sinks-after-mid-stage-data-from-fatty-liver-candidate">"Altimmune stock sinks after mid‑stage data from fatty liver candidate"</a>, by Vandana Singh, reports that Altimmune Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares plunged after its Phase 2b trial showed pemvidutide resolved MASH in over half of treated patients (59.1% at 1.2 mg and 52.1% at 1.8 mg) with significant liver‑fat reduction, but missed the fibrosis endpoint — prompting broad investor concern.
<a href="https://www.benzinga.com/news/space/25/06/46055895/ast-spacemobile-stock-downgraded-rocket-lab-prepares-electron-launch-space-stock-countdown">"AST SpaceMobile stock downgraded, Rocket Lab prepares Electron launch: Space stock countdown"</a>, by Erica Kollmann, reports that AST SpaceMobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) was downgraded by Scotiabank to Sector Perform with a $45.40 target, even as Rocket Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gears up for another Electron launch — factors highlighting heightened volatility in space stocks.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/markets/earnings/25/06/46083155/aerovironment-stock-sinks-despite-better-than-expected-q4-report-heres-why">AeroVironment Stock Sinks Despite Better-Than-Expected Q4 Report: Here's Why</a>
<a href="https://www.benzinga.com/markets/earnings/25/06/46128371/concentrix-stock-slips-after-mixed-q2-results-details">Concentrix Stock Slips After Mixed Q2 Results: Details</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46118143/unity-software-stock-is-sliding-today-whats-going-on">Unity Software Stock Is Sliding Today: What's Going On?</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

ASTS

AVAV

CNXC

PLTR

PONY

RKLB

Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief

Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if genetic factors impact the risk of acute pancreatitis associated with GLP-1 injections.
Yellow Card Biobank, a collaboration between the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, will start investigating whether the risk of acute pancreatitis (inflamed pancreas) from GLP-1 injections for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">weight loss and Type 2 diabetes</a> may be influenced by an individual&#8217;s genes.
The agency <a target="_blank" href="https://www.gov.uk/government/news/if-you-take-a-glp-1-medicine-and-have-been-hospitalised-by-acute-pancreatitis-the-yellow-card-biobank-wants-to-hear-from-you" rel="noreferrer noopener">said</a> in a statement on Thursday that although infrequent, acute pancreatitis has been reported with GLP-1 medicines.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows" rel="noreferrer noopener">US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows</a>
Patients hospitalized with <a href="https://www.benzinga.com/general/biotech/23/10/35123873/novo-nordisks-weight-loss-drugs-like-wegovy-ozempic-may-pose-serious-stomach-risks-study-suggests" target="_blank" rel="noreferrer noopener">acute pancreatitis suspected </a>to be related to glucagon-like peptide-1 receptor agonists (GLP-1 medicines), such as Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic (semaglutide) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro (Tirzepatide), are asked to report it to the MHRA&#8217;s&nbsp;Yellow Card scheme.
These medicines are sometimes referred to colloquially as &#8220;skinny jabs,&#8221; although they are licensed for both weight loss and Type 2 diabetes.&nbsp;
Healthcare professionals are also being asked to help recruit for the study by reporting Yellow Cards on behalf of patients experiencing acute pancreatitis while taking GLP-1 medicines.&nbsp;
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to participate in the Biobank study.
This would involve providing further information and submitting a saliva or spit sample, which will be used to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genetic makeup.
Dr Alison Cave, MHRA Chief Safety Officer, said, &#8220;Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing. It is predicted that adverse drug reactions cost the NHS more than 2.2 billion pounds ($3.02 billion) a year in hospital stays alone.&#8221;
On June 19, Spain&#8217;s Ministry of Health, through the General Directorate of the Common Portfolio of Services of the National Health System (NHS) and Pharmacy, requested information from Novo Nordisk Pharma after detecting indications that one of its information portals may be <a href="https://www.bmj.com/content/389/bmj.r1319" target="_blank" rel="noreferrer noopener">violating</a> regulations regarding drug advertising.
The initiative follows a media report <a target="_blank" href="https://www.sanidad.gob.es/en/gabinete/notasPrensa.do?id=6699" rel="noreferrer noopener">about</a> a website, which redirects to another page called &#8220;Obesity without filters,&#8221; managed by the laboratory. It presents informative content related to the approach to obesity, including images expressly indicating that this is a Novo Nordisk initiative endorsed by various scientific societies.
The Ministry has formally requested that the company provide documentation regarding the endorsement declared by these scientific and professional organizations.
It has also drawn attention to another link on the website containing recommended questions for the doctor. Although no pharmacological treatment is explicitly mentioned, the Ministry believes that the content could constitute indirect advertising for prescription drugs, the public promotion of which is prohibited under current legislation.
Meanwhile, Novo Nordisk continues the expansion of patient access to Wegovy (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers beginning&nbsp;July 1, 2025.
WeightWatchers&nbsp;will <a target="_blank" href="https://www.prnewswire.com/news-releases/novo-nordisk-continues-efforts-to-support-patient-access-to-authentic-fda-approved-wegovy-and-prioritize-patient-safety-302492419.html" rel="noreferrer noopener">work</a> with&nbsp;CenterWell&nbsp;Pharmacy as the dispensing pharmacy managing prescription fulfillment and delivery for NovoCare Pharmacy.
Novo Nordisk said on Thursday that it is also introducing a new cash-offer price of&nbsp;$299, available through&nbsp;July 31, 2025.
This&nbsp;$299&nbsp;introductory price is available for self-paying patients new to the Wegovy&nbsp;savings offer or those who have not previously filled a prescription through NovoCare&nbsp;Pharmacy.
This builds on the previous&nbsp;$199&nbsp;Wegovy&nbsp;cash-offer patient price that expires on&nbsp;June 30, 2025.
Patients who redeemed the&nbsp;$199&nbsp;Wegovy&nbsp;savings offer&nbsp;between May 22 and June 30, 2025, will be eligible for the&nbsp;$299&nbsp;price on one fill&nbsp;between July 1 and July 31.
For subsequent months, self-paying patients will pay&nbsp;$499&nbsp;per month.
The company said in a press release that with all doses of FDA-approved Wegovy fully available nationwide, it is illegal under <a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">U.S. compounding laws</a> to make or sell knockoff &#8220;semaglutide&#8221; drugs, with rare exceptions.&nbsp;
Price Action: NVO stock is up 1.77% at $68.90 during the premarket session at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46136734/rfk-jrs-cdc-panel-recommends-mercks-rsv-shot-for-infants" target="_blank" rel="noreferrer noopener">RFK Jr&#8217;s CDC Panel Recommends Merck&#8217;s RSV Shot For Infants</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk endorsed&nbsp;Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Satya Nadella&#8217;s&nbsp;perspective on&nbsp;the practical impact of AI, emphasizing its&nbsp;benefits to sectors like healthcare,&nbsp;education, and productivity.
What Happened: Musk, on X, supported Nadella&#8217;s views on AI&#8217;s progress, which were shared in a post by Nadella on June 25, 2025. Nadella, the CEO of&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), had stressed the importance of AI&#8217;s real-world outcomes over technical benchmarks at Y Combinator&#8217;s&nbsp;AI Startup School wherein Elon Musk commented &#8220;True&#8221;. Nadella stated that AI must produce results that are &#8220;socially useful.&#8221;
This shift in focus aligns with recent studies indicating AI&#8217;s&nbsp;potential to enhance GDP growth&nbsp;by addressing real-world challenges.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">True <a href="https://t.co/iFlmTUzLwx">https://t.co/iFlmTUzLwx</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1938086636941939098?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;If we really are not creating social surplus, economic surplus, as measured by countries and communities, we just can&#8217;t consumer energy.&#8221; stated Nadella. 
&#8220;The real question in the next five years is we&#8217;ve got to produce enough products that are creating great value,&#8221; he added.
He also pointed out&nbsp;that the true measure of&nbsp;AI&#8217;s progress lies in&nbsp;its ability to improve real-world&nbsp;outcomes rather than just achieving&nbsp;technical benchmarks. 
SEE ALSO: <a href="https://benzinga.com/crypto/25/06/46131453/bitcoin-ethereum-rangebound-dogecoin-dips-amid-potential-july-tariff-deadline-extension-analyst-predicts-btcs-next-big-move-once-it-breaks-out-of-this-range" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Rangebound, Dogecoin Dips Amid Potential July Tariff Deadline Extension: Analyst Predicts BTC&#8217;s &#8216;Next Big Move&#8217; Once It Breaks Out Of This Range </a>
Why It Matters:&nbsp;Musk&#8217;s endorsement of Nadella&#8217;s view on AI&#8217;s real progress comes at a time when the tech industry is witnessing a shift towards focusing on&nbsp;the practical impact of AI.
CEO Satya Nadella believes that while AI is already <a href="https://www.benzinga.com/markets/tech/25/06/46111393/ai-is-already-speeding-up-discoveries-in-chemistry-and-physics-but-satya-nadella-says-the-real-breakthrough-will-come-when-we-add-quantum-computing-to-the-mix">driving major</a> scientific breakthroughs, its full transformative potential will be unlocked with the integration of quantum computing. Meanwhile, the growing role of AI in healthcare was highlighted, with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) partnering with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to speed up drug discovery and development. 
However, Wall Street remains divided on AI's future—while some investors are optimistic about its disruptive potential, others express concerns over associated risks and the lack of transparency in how it is being managed.
On a year-to-date basis, ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>) climbed 24.85% and 13.05%, respectively. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46127671/amazon-loses-top-ai-leader-in-high-stakes-talent-shuffle">Amazon Loses Top AI Leader In High-Stakes Talent Shuffle </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ARKK

Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...'

Legal

Press Releases

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

Small Cap

From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room

New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety

AVAI

TDOC

TNDM

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

BMO Capital

Cantor Fitzgerald

Argus Research

Morgan Stanley

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Comments

Novo Nordisk

Noticias

Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL